Hemoglobin-based oxygen carriers.

Hemoglobin-based oxygen carriers.
复制标题

DOI:
10.1186/cc2455
复制
发表时间:
2004
期刊:
Critical care (London, England)
影响因子:
--
通讯作者:
Kim HW
Kim HW
中科院分区:
其他
文献类型:
--
作者:
Greenburg AG;Kim HW

文献摘要

参考文献

被引文献

相似文献

可用作红细胞输注替代品的可输注液体提供了保留组织灌注和最小化缺氧细胞损伤的承诺,并且这一承诺可能很快就会实现。基于血红蛋白的氧载体的临床测试面临并满足了涉及分子设计、安全性、有效性和监管要求的挑战。已经出现了三种主要候选物:两种人血红蛋白溶液(PolyHeme®和HemoLink™)和一种牛血红蛋白溶液(Hemopure®)。由于难以证明生存获益,因此采用避免同种异体输血作为这些药物的标准疗效终点。提供了临床试验状态的更新,并讨论了血红蛋白为基础的氧载体在手术中结合术中自体捐献的潜在效用。
Transfusable fluids that may be used as alternatives to red blood cell transfusion offer the promise of preserving tissue perfusion and minimizing hypoxic cellular damage, and this promise may soon be fulfilled. Clinical testing of hemoglobin-based oxygen carriers has faced and met challenges involving molecular design, safety, efficacy, and regulatory requirements. Three leading candidates have emerged: two human (PolyHeme® and HemoLink™) and one bovine-based hemoglobin solution (Hemopure®). Because a survival benefit has been difficult to demonstrate, avoidance of allogeneic transfusion has been adopted as the standard efficacy end-point for these agents. An update on clinical trial status is provided, and the potential utility of hemoglobin-based oxygen carriers in surgery combined with intraoperative autologous donation is discussed.
DOI: 10.1067/mtc.2002.121505
发表时间: 2002-07-01
影响因子: 6
作者:
Levy, JH;Goodnough, LT;Vlahakes, GJ
通讯作者: Vlahakes, GJ
DOI: 10.1016/s0002-9610(99)80058-0
发表时间: 1995-12-01
影响因子: 3
作者:
Greenburg, AG
通讯作者: Greenburg, AG
DOI: 10.1016/s0022-2143(00)70023-0
发表时间: 2000-01-01
期刊: JOURNAL OF LABORATORY AND CLINICAL MEDICINE
影响因子: --
作者:
Lieberthal, W;Fuhro, R;Valeri, CR
通讯作者: Valeri, CR
DOI: 10.1053/jcan.2002.128416
发表时间: 2002-12-01
影响因子: 2.8
作者:
Hill, SE;Gottschalk, LI;Grichnik, K
通讯作者: Grichnik, K
DOI: 10.1097/00003246-200007000-00017
发表时间: 2000-07-01
影响因子: 8.8
作者:
Carmichael, FJL;Ali, ACY;Greenburg, AG
通讯作者: Greenburg, AG